Please ensure Javascript is enabled for purposes of website accessibility
Recent News
Home / Wire Stories / Patent ‘shenanigans’ keep drug costs high

Patent ‘shenanigans’ keep drug costs high

Bob Kelsey can’t afford a cancer drug that could save his life. The retired firefighter, 53, needs Revlimid to stay healthy. Celgene Corp. has raised the price 88 percent over the past seven years. The drug doesn’t have substantial competition from a less expensive generic version, and probably won’t for another eight years. Celgene has worked hard to make sure ...

About Bloomberg News

Leave a Reply